Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
Investor Relations
Filing Reader · Print Documents · Transcripts
Could not find a transcript
Peer Group
Peers Analysis-
Sorry! None of DNLI's peers has listed transcripts.
Upcoming Transcript Tools
- Full Text Search - Across All Transcripts
- Detail Speaker Profiles
- Non-US Transcripts